PMC:7306567 / 15801-16137 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"165","span":{"begin":298,"end":311},"obj":"Disease"}],"attributes":[{"id":"A165","pred":"tao:has_database_id","subj":"165","obj":"MESH:D008286"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"disease following alloHCT [2, 3]. Based on this proof-of-principle, it has been hypothesized that POS prophylaxis can reduce IAPA prevalence in ICU patients. Intravenous (IV) administration of POS prophylaxis in the ICU is favored in patients on mechanical ventilation or with a high likelihood of malabsorption of oral formulations. PO"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T80","span":{"begin":298,"end":311},"obj":"Disease"}],"attributes":[{"id":"A80","pred":"mondo_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/MONDO_0020598"}],"text":"disease following alloHCT [2, 3]. Based on this proof-of-principle, it has been hypothesized that POS prophylaxis can reduce IAPA prevalence in ICU patients. Intravenous (IV) administration of POS prophylaxis in the ICU is favored in patients on mechanical ventilation or with a high likelihood of malabsorption of oral formulations. PO"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T99","span":{"begin":71,"end":74},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T100","span":{"begin":277,"end":278},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"disease following alloHCT [2, 3]. Based on this proof-of-principle, it has been hypothesized that POS prophylaxis can reduce IAPA prevalence in ICU patients. Intravenous (IV) administration of POS prophylaxis in the ICU is favored in patients on mechanical ventilation or with a high likelihood of malabsorption of oral formulations. PO"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T101","span":{"begin":171,"end":173},"obj":"Chemical"}],"attributes":[{"id":"A101","pred":"chebi_id","subj":"T101","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"}],"text":"disease following alloHCT [2, 3]. Based on this proof-of-principle, it has been hypothesized that POS prophylaxis can reduce IAPA prevalence in ICU patients. Intravenous (IV) administration of POS prophylaxis in the ICU is favored in patients on mechanical ventilation or with a high likelihood of malabsorption of oral formulations. PO"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T27","span":{"begin":298,"end":311},"obj":"Phenotype"}],"attributes":[{"id":"A27","pred":"hp_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/HP_0002024"}],"text":"disease following alloHCT [2, 3]. Based on this proof-of-principle, it has been hypothesized that POS prophylaxis can reduce IAPA prevalence in ICU patients. Intravenous (IV) administration of POS prophylaxis in the ICU is favored in patients on mechanical ventilation or with a high likelihood of malabsorption of oral formulations. PO"}

{"project":"LitCovid-sentences","denotations":[{"id":"T105","span":{"begin":34,"end":157},"obj":"Sentence"},{"id":"T106","span":{"begin":158,"end":333},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"disease following alloHCT [2, 3]. Based on this proof-of-principle, it has been hypothesized that POS prophylaxis can reduce IAPA prevalence in ICU patients. Intravenous (IV) administration of POS prophylaxis in the ICU is favored in patients on mechanical ventilation or with a high likelihood of malabsorption of oral formulations. PO"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T119","span":{"begin":315,"end":319},"obj":"UBERON:0000165"},{"id":"T65652","span":{"begin":315,"end":319},"obj":"UBERON:0000165"}],"text":"disease following alloHCT [2, 3]. Based on this proof-of-principle, it has been hypothesized that POS prophylaxis can reduce IAPA prevalence in ICU patients. Intravenous (IV) administration of POS prophylaxis in the ICU is favored in patients on mechanical ventilation or with a high likelihood of malabsorption of oral formulations. PO"}